Long-term spontaneous control of HIV-1 is related to low frequency of infected cells and inefficient viral reactivation

Journal of Virology

Volumn 90, Issue 13, 2016, Pages 6148-6158

  Noel, Nicolas ^a,b,c,d   Peña, Ruth ^e   David, Annie ^f   Avettand Fenoel, Veronique ^g,h   Erkizia, Itziar ^e   Jimenez, Esther ^e   Lecuroux, Camille ^a,c   Rouzioux, Christine ^g,h   Boufassa, Faroudy ^c   Pancino, Gianfranco ^f   Venet, Alain ^a   Van Lint, Carine ⁱ   Martinez Picado, Javier ^e,j,k   Lambotte, Olivier ^a,b,c,d   Sáez Cirión, Asier ^f   Prado, Julia G ^e  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^c INSERM   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^f INSTITUT PASTEUR   (France)

^g HÔPITAL NECKER ENFANTS MALADES   (France)

^h UNIVERSITÉ PARIS DESCARTES   (France)

ⁱ UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^j UNIVERSITY OF VIC CENTRAL UNIVERSITY OF CATALONIA   (Spain)

^k INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRUS RNA;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; MIDDLE AGED; NONHUMAN; PRIORITY JOURNAL; VIRION; VIROGENESIS; VIRUS LOAD; VIRUS REACTIVATION; BLOOD; GROWTH, DEVELOPMENT AND AGING; HIV INFECTIONS; IMMUNOLOGY; ISOLATION AND PURIFICATION; PHYSIOLOGY; VIROLOGY; VIRUS ACTIVATION; VIRUS LATENCY; VIRUS REPLICATION;

ADULT; AGED; ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; RNA, VIRAL; VIRUS ACTIVATION; VIRUS LATENCY; VIRUS REPLICATION;

EID: 84975297420     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00419-16     Document Type: Article

References (56)

1. Saez-Cirion A, Pancino G. 2013. HIV controllers: a genetically determined or inducible phenotype? Immunol Rev 254:281-294. http://dx.doi.org/10.1111/imr.12076.
2. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, Lederman MM, Benito JM, Goepfert PA, Connors M, Roederer M, Koup RA. 2006. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8α T cells. Blood 107:4781-4789. http://dx.doi.org/10.1182/blood-2005-12-4818.
3. Migueles SA, Laborico AC, Shupert WL, Sabbaghian MS, Rabin R, Hallahan CW, Van Baarle D, Kostense S, Miedema F, McLaughlin M, Ehler L, Metcalf J, Liu S, Connors M. 2002. HIV-specific CD8α T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 3:1061-1068. http://dx.doi.org/10.1038/ni845.
4. Saez-Cirion A, Lacabaratz C, Lambotte O, Versmisse P, Urrutia A, Boufassa F, Barre-Sinoussi F, Delfraissy JF, Sinet M, Pancino G, Venet A. 2007. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad SciUSA104:6776-6781. http://dx.doi.org/10.1073/pnas.0611244104.
5. Flores-Villanueva PO, Yunis EJ, Delgado JC, Vittinghoff E, Buchbinder S, Leung JY, Uglialoro AM, Clavijo OP, Rosenberg ES, Kalams SA, Braun JD, Boswell SL, Walker BD, Goldfeld AE. 2001. Control of HIV-1 viremia and protection from AIDS are associated with HLA-Bw4 homozygosity. Proc Natl Acad Sci U S A 98:5140-5145. http://dx.doi.org/10.1073/pnas.071548198.
6. Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, Martino L, Hallahan CW, Selig SM, Schwartz D, Sullivan J, Connors M. 2000. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci U S A 97:2709-2714. http://dx.doi.org/10.1073/pnas.050567397.
7. Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, Walker BD, Ripke S, Brumme CJ, Pulit SL, Carrington M, Kadie CM, Carlson JM, Heckerman D, Graham RR, Plenge RM, Deeks SG, Gianniny L, Crawford G, Sullivan J, Gonzalez E, Davies L, Camargo A, Moore JM, Beattie N, Gupta S, Crenshaw A, Burtt NP, Guiducci C, Gupta N, Gao X, Qi Y, Yuki Y, Piechocka-Trocha A, Cutrell E, Rosenberg R, Moss KL, Lemay P, O'Leary J, Schaefer T, Verma P, Toth I, Block B, Baker B, Rothchild A, Lian J, Proudfoot J, Alvino DM, Vine S, Addo MM, Allen TM, et al. 2010. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 330:1551-1557. http://dx.doi.org/10.1126/science.1195271.
8. Lecuroux C, Saez-Cirion A, Girault I, Versmisse P, Boufassa F, Avettand-Fenoel V, Rouzioux C, Meyer L, Pancino G, Lambotte O, Sinet M, Venet A. 2014. Both HLA-B*57 and plasma HIV RNA levels contribute to the HIV-specific CD8α T cell response in HIV controllers. J Virol 88:176-187. http://dx.doi.org/10.1128/JVI.02098-13.
9. Saez-Cirion A, Sinet M, Shin SY, Urrutia A, Versmisse P, Lacabaratz C, Boufassa F, Avettand-Fenoel V, Rouzioux C, Delfraissy JF, Barre-Sinoussi F, Lambotte O, Venet A, Pancino G. 2009. Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses. J Immunol 182:7828-7837. http://dx.doi.org/10.4049/jimmunol.0803928.
10. Bruel T, Hamimi C, Dereuddre-Bosquet N, Cosma A, Shin SY, Corneau A, Versmisse P, Karlsson I, Malleret B, Targat B, Barre-Sinoussi F, Le Grand R, Pancino G, Saez-Cirion A, Vaslin B. 2015. Long-term control of simian immunodeficiency virus (SIV) in cynomolgus macaques not associated with efficient SIV-specific CD8α T-cell responses. J Virol 89: 3542-3556. http://dx.doi.org/10.1128/JVI.03723-14.
11. Addo MM, Draenert R, Rathod A, Verrill CL, Davis BT, Gandhi RT, Robbins GK, Basgoz NO, Stone DR, Cohen DE, Johnston MN, Flynn T, Wurcel AG, Rosenberg ES, Altfeld M, Walker BD. 2007. Fully differentiated HIV-1 specific CD8α T effector cells are more frequently detectable in controlled than in progressive HIV-1 infection. PLoS One 2:e321. http://dx.doi.org/10.1371/journal.pone.0000321.
12. Ndhlovu ZM, Proudfoot J, Cesa K, Alvino DM, McMullen A, Vine S, Stampouloglou E, Piechocka-Trocha A, Walker BD, Pereyra F. 2012. Elite controllers with low to absent effector CD8α T cell responses maintain highly functional, broadly directed central memory responses. J Virol 86:6959-6969. http://dx.doi.org/10.1128/JVI.00531-12.
13. Blankson JN, Bailey JR, Thayil S, Yang HC, Lassen K, Lai J, Gandhi SK, Siliciano JD, Williams TM, Siliciano RF. 2007. Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J Virol 81:2508-2518. http://dx.doi.org/10.1128/JVI.02165-06.
14. Lamine A, Caumont-Sarcos A, Chaix ML, Saez-Cirion A, Rouzioux C, Delfraissy JF, Pancino G, Lambotte O. 2007. Replication-competent HIV strains infect HIV controllers despite undetectable viremia (ANRS EP36 study). AIDS 21:1043-1045. http://dx.doi.org/10.1097/QAD.0b013e3280d5a7ac.
15. Miura T, Brockman MA, Brumme CJ, Brumme ZL, Carlson JM, Pereyra F, Trocha A, Addo MM, Block BL, Rothchild AC, Baker BM, Flynn T, Schneidewind A, Li B, Wang YE, Heckerman D, Allen TM, Walker BD. 2008. Genetic characterization of human immunodeficiency virus type 1 in elite controllers: lack of gross genetic defects or common amino acid changes. J Virol 82:8422-8430. http://dx.doi.org/10.1128/JVI.00535-08.
16. Lewin SR, Rouzioux C. 2011. HIV cure and eradication: how will we get from the laboratory to effective clinical trials? AIDS 25:885-897. http://dx.doi.org/10.1097/QAD.0b013e3283467041.
17. Saez-Cirion A, Hamimi C, Bergamaschi A, David A, Versmisse P, Melard A, Boufassa F, Barre-Sinoussi F, Lambotte O, Rouzioux C, Pancino G. 2011. Restriction of HIV-1 replication in macrophages and CD4α T cells from HIV controllers. Blood 118:955-964. http://dx.doi.org/10.1182/blood-2010-12-327106.
18. Hill AL, Rosenbloom DI, Fu F, Nowak MA, Siliciano RF. 2014. Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1. Proc Natl Acad Sci U S A 111:13475-13480. http://dx.doi.org/10.1073/pnas.1406663111.
19. Assoumou L, Weiss L, Piketty C, Burgard M, Melard A, Girard P-M, Rouzioux C, Costagliola D, ANRS 116 SALTO Study Group. 2015. A low HIV-DNA level in PBMCs at antiretroviral treatment interruption predicts a higher probability of maintaining viral control. AIDS 29:2003-2007. http://dx.doi.org/10.1097/QAD.0000000000000734.
20. Goujard C, Girault I, Rouzioux C, Lecuroux C, Deveau C, Chaix ML, Jacomet C, Talamali A, Delfraissy JF, Venet A, Meyer L, Sinet M. 2012. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy. Antivir Ther 17:1001-1009. http://dx.doi.org/10.3851/IMP2273.
21. Hocqueloux L, Prazuck T, Avettand-Fenoel V, Lafeuillade A, Cardon B, Viard JP, Rouzioux C. 2010. Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. AIDS 24:1598-1601. http://dx.doi.org/10.1097/QAD.0b013e32833b61ba.
22. Yerly S, Gunthard HF, Fagard C, Joos B, Perneger TV, Hirschel B, Perrin L. 2004. Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions. AIDS 18:1951-1953. http://dx.doi.org/10.1097/00002030-200409240-00011.
23. Henrich TJ, Hanhauser E, Marty FM, Sirignano MN, Keating S, Lee TH, Robles YP, Davis BT, Li JZ, Heisey A, Hill AL, Busch MP, Armand P, Soiffer RJ, Altfeld M, Kuritzkes DR. 2014. Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med 161:319-327. http://dx.doi.org/10.7326/M14-1027.
24. Reuse S, Calao M, Kabeya K, Guiguen A, Gatot JS, Quivy V, Vanhulle C, Lamine A, Vaira D, Demonte D, Martinelli V, Veithen E, Cherrier T, Avettand V, Poutrel S, Piette J, de Launoit Y, Moutschen M, Burny A, Rouzioux C, De Wit S, Herbein G, Rohr O, Collette Y, Lambotte O, Clumeck N, Van Lint C. 2009. Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS One 4:e6093. http://dx.doi.org/10.1371/journal.pone.0006093.
25. Rouet F, Chaix ML, Nerrienet E, Ngo-Giang-Huong N, Plantier JC, Burgard M, Peeters M, Damond F, Ekouevi DK, Msellati P, Ferradini L, Rukobo S, Marechal V, Schvachsa N, Wakrim L, Rafalimanana C, Rakotoambinina B, Viard JP, Seigneurin JM, Rouzioux C. 2007. Impact of HIV-1 genetic diversity on plasma HIV-1 RNA quantification: usefulness of the Agence Nationale de Recherches sur le SIDA secondgeneration long terminal repeat-based real-time reverse transcriptase polymerase chain reaction test. J Acquir Immune Defic Syndr 45:380-388. http://dx.doi.org/10.1097/QAI.0b013e3180640cf5.
26. Avettand-Fenoel V, Chaix ML, Blanche S, Burgard M, Floch C, Toure K, Allemon MC, Warszawski J, Rouzioux C. 2009. LTR real-time PCR for HIV-1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01). J Med Virol 81:217-223. http://dx.doi.org/10.1002/jmv.21390.
27. Avettand-Fenoel V, Prazuck T, Hocqueloux L, Melard A, Michau C, Kerdraon R, Agoute E, Rouzioux C. 2008. HIV-DNA in rectal cells is well correlated with HIV-DNA in blood in different groups of patients, including long-term non-progressors. AIDS 22:1880-1882. http://dx.doi.org/10.1097/QAD.0b013e32830fbdbc.
28. Dalmau J, Codoner FM, Erkizia I, Pino M, Pou C, Paredes R, Clotet B, Martinez-Picado J, Prado JG. 2012. In-depth characterization of viral isolates from plasma and cells compared with plasma circulating quasispecies in early HIV-1 infection. PLoS One 7:e32714. http://dx.doi.org/10.1371/journal.pone.0032714.
29. Prado JG, Prendergast A, Thobakgale C, Molina C, Tudor-Williams G, Ndung'u T, Walker BD, Goulder P. 2010. Replicative capacity of human immunodeficiency virus type 1 transmitted from mother to child is associated with pediatric disease progression rate. J Virol 84:492-502. http://dx.doi.org/10.1128/JVI.01743-09.
30. Saez-Cirion A, Shin SY, Versmisse P, Barre-Sinoussi F, Pancino G. 2010. Ex vivo T cell-based HIV suppression assay to evaluate HIV-specific CD8α T-cell responses. Nat Protoc 5:1033-1041. http://dx.doi.org/10.1038/nprot.2010.73.
31. Ho YC, Shan L, Hosmane NN, Wang J, Laskey SB, Rosenbloom DI, Lai J, Blankson JN, Siliciano JD, Siliciano RF. 2013. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155:540-551. http://dx.doi.org/10.1016/j.cell.2013.09.020.
32. Laird GM, Bullen CK, Rosenbloom DI, Martin AR, Hill AL, Durand CM, Siliciano JD, Siliciano RF. 2015. Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. J Clin Invest 125:1901-1912. http://dx.doi.org/10.1172/JCI80142.
33. Darcis G, Kula A, Bouchat S, Fujinaga K, Corazza F, Ait-Ammar A, Delacourt N, Melard A, Kabeya K, Vanhulle C, Van Driessche B, Gatot J-S, Cherrier T, Pianowski LF, Gama L, Schwartz C, Vila J, Burny A, Clumeck N, Moutschen M, De Wit S, Peterlin BM, Rouzioux C, Rohr O, Van Lint C. 2015. an in-depth comparison of latency-reversing agent combinations in various in vitro and ex vivo HIV-1 latency models identified bryostatin-1αJQ1 and ingenol-BαJQ1 to potently reactivate viral gene expression. PLoS Pathog 11:e1005063. http://dx.doi.org/10.1371/journal.ppat.1005063.
34. Shuai K, Liu B. 2003. Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol 3:900-911. http://dx.doi.org/10.1038/nri1226.
35. Williams SA, Chen LF, Kwon H, Fenard D, Bisgrove D, Verdin E, Greene WC. 2004. Prostratin antagonizes HIV latency by activating NF-kappaB. J Biol Chem 279:42008-42017. http://dx.doi.org/10.1074/jbc.M402124200.
36. Contreras X, Barboric M, Lenasi T, Peterlin BM. 2007. HMBA releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and activates HIV transcription. PLoS Pathog 3:1459-1469.
37. Kauder SE, Bosque A, Lindqvist A, Planelles V, Verdin E. 2009. Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog 5:e1000495. http://dx.doi.org/10.1371/journal.ppat.1000495.
38. Bouchat S, Gatot JS, Kabeya K, Cardona C, Colin L, Herbein G, De Wit S, Clumeck N, Lambotte O, Rouzioux C, Rohr O, Van Lint C. 2012. Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4(α) T cells from HIV-1-infected HAART-treated patients. AIDS 26: 1473-1482. http://dx.doi.org/10.1097/QAD.0b013e32835535f5.
39. Archin NM, Espeseth A, Parker D, Cheema M, Hazuda D, Margolis DM. 2009. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses 25: 207-212. http://dx.doi.org/10.1089/aid.2008.0191.
40. Chen H, Li C, Huang J, Cung T, Seiss K, Beamon J, Carrington MF, Porter LC, Burke PS, Yang Y, Ryan BJ, Liu R, Weiss RH, Pereyra F, Cress WD, Brass AL, Rosenberg ES, Walker BD, Yu XG, Lichterfeld M. 2011. CD4α T cells from elite controllers resist HIV-1 infection by selective upregulation of p21. J Clin Invest 121:1549-1560. http://dx.doi.org/10.1172/JCI44539.
41. O'Connell KA, Brennan TP, Bailey JR, Ray SC, Siliciano RF, Blankson JN. 2010. Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus. J Virol 84:7018-7028. http://dx.doi.org/10.1128/JVI.00548-10.
42. Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, Rathod A, Baker B, Trocha A, Rosenberg R, Mackey E, Ueda P, Lu Z, Cohen D, Wrin T, Petropoulos CJ, Rosenberg ES, Walker BD. 2008. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis 197:563-571. http://dx.doi.org/10.1086/526786.
43. Saez-Cirion A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C, Potard V, Versmisse P, Melard A, Prazuck T, Descours B, Guergnon J, Viard JP, Boufassa F, Lambotte O, Goujard C, Meyer L, Costagliola D, Venet A, Pancino G, Autran B, Rouzioux C. 2013. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 9:e1003211. http://dx.doi.org/10.1371/journal.ppat.1003211.
44. Julg B, Williams KL, Reddy S, Bishop K, Qi Y, Carrington M, Goulder PJ, Ndung'u T, Walker BD. 2010. Enhanced anti-HIV functional activity associated with Gag-specific CD8 T-cell responses. J Virol 84:5540-5549. http://dx.doi.org/10.1128/JVI.02031-09.
45. Crowell TA, Gebo KA, Blankson JN, Korthuis PT, Yehia BR, Rutstein RM, Moore RD, Sharp V, Nijhawan AE, Mathews WC, Hanau LH, Corales RB, Beil R, Somboonwit C, Edelstein H, Allen SL, Berry SA. 2015. Hospitalization rates and reasons among HIV elite controllers and persons with medically controlled HIV infection. J Infect Dis 211:1692-1702. http://dx.doi.org/10.1093/infdis/jiu809.
46. Hatano H, Yukl SA, Ferre AL, Graf EH, Somsouk M, Sinclair E, Abdel-Mohsen M, Liegler T, Harvill K, Hoh R, Palmer S, Bacchetti P, Hunt PW, Martin JN, McCune JM, Tracy RP, Busch MP, O'Doherty U, Shacklett BL, Wong JK, Deeks SG. 2013. Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers. PLoS Pathog 9:e1003691. http://dx.doi.org/10.1371/journal.ppat.1003691.
47. Boufassa F, Saez-Cirion A, Lechenadec J, Zucman D, Avettand-Fenoel V, Venet A, Rouzioux C, Delfraissy JF, Lambotte O, Meyer L. 2011. CD4 dynamics over a 15 year-period among HIV controllers enrolled in the ANRS French observatory. PLoS One 6:e18726. http://dx.doi.org/10.1371/journal.pone.0018726.
48. Chun TW, Justement JS, Murray D, Kim CJ, Blazkova J, Hallahan CW, Benko E, Costiniuk CT, Kandel G, Ostrowski M, Kaul R, Moir S, Casazza JP, Koup RA, Kovacs C, Fauci AS. 2013. Effect of antiretroviral therapy on HIV reservoirs in elite controllers. J Infect Dis 208:1443-1447. http://dx.doi.org/10.1093/infdis/jit306.
49. Persaud D, Luzuriaga K. 2014. Absence of HIV-1 after treatment cessation in an infant. N Engl J Med 370:678. http://dx.doi.org/10.1056/NEJMc1315498.
50. Ndhlovu ZM, Stampouloglou E, Cesa K, Mavrothalassitis O, Alvino DM, Li JZ, Wilton S, Karel D, Piechocka-Trocha A, Chen H, Pereyra F, Walker BD. 2015. The breadth of expandable memory CD8α T cells inversely correlates with residual viral loads in HIV elite controllers. J Virol 89:10735-10747. http://dx.doi.org/10.1128/JVI.01527-15.
51. Nasi M, Pinti M, Manzini S, Gibellini L, Manzini L, Bisi L, De Biasi S, Del Giovane C, D'Amico R, Borghi V, Mussini C, Cossarizza A. 2010. Predictive value of intracellular HIV-1 DNA levels during CD4-guided treatment interruption in HIVα patients. AIDS Res Hum Retroviruses 26:553-558. http://dx.doi.org/10.1089/aid.2009.0256.
52. Goujard C, Bonarek M, Meyer L, Bonnet F, Chaix ML, Deveau C, Sinet M, Galimand J, Delfraissy JF, Venet A, Rouzioux C, Morlat P. 2006. CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. Clin Infect Dis 42:709-715. http://dx.doi.org/10.1086/500213.
53. Rouzioux C, Hubert JB, Burgard M, Deveau C, Goujard C, Bary M, Sereni D, Viard JP, Delfraissy JF, Meyer L. 2005. Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4α T cell counts. J Infect Dis 192:46-55. http://dx.doi.org/10.1086/430610.
54. Kiselinova M, De Spiegelaere W, Buzon MJ, Malatinkova E, Lichterfeld M, Vandekerckhove L. 2016. Integrated and total HIV-1 DNA predict ex vivo viral outgrowth. PLoS Pathog 12:e1005472. http://dx.doi.org/10.1371/journal.ppat.1005472.
55. Leng J, Ho HP, Buzon MJ, Pereyra F, Walker BD, Yu XG, Chang EJ, Lichterfeld M. 2014. A cell-intrinsic inhibitor of HIV-1 reverse transcription in CD4(α) T cells from elite controllers. Cell Host Microbe 15:717-728. http://dx.doi.org/10.1016/j.chom.2014.05.011.
56. Buckheit RW, III, Allen TG, Alme A, Salgado M, O'Connell KA, Huculak S, Falade-Nwulia O, Williams TM, Gallant JE, Siliciano RF, Blankson JN. 2012. Host factors dictate control of viral replication in two HIV-1 controller/chronic progressor transmission pairs. Nat Commun 3:716. http://dx.doi.org/10.1038/ncomms1697.